AbbVie reports positive results for migraine drug in Phase 3 trial, meeting primary endpoint.

From Yahoo Finance: 2025-06-24 17:21:00

AbbVie Inc. (NYSE:ABBV) reported positive results in its Phase 3 TEMPLE study for atogepant, a preventive treatment for migraines. Atogepant met its primary endpoint and showed fewer adverse events compared to topiramate.

Atogepant is an oral medication that blocks CGRP to prevent migraine attacks. AbbVie is a biopharmaceutical company with global operations, focusing on various therapeutic areas like immunology and oncology. Key products include Humira and Botox.

While AbbVie shows promise, some AI stocks offer more upside potential. For an undervalued AI stock benefiting from current trends, check out the free report on the best short-term AI stock.

Read more: AbbVie (ABBV) Reports Positive Migraine Drug Results in Phase 3 Trial